论文信息 - Phase 2 Open‐Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle‐Cell and Indolent Lymphomas - 字舞流文

Phase 2 Open‐Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle‐Cell and Indolent Lymphomas

D. Mahadevan | J. Schatz | J. Guillén-Rodríguez | D. Persky | F. Anwer | Abhijeet Kumar | S. Puvvada | L. Inclán | K. Heard | Xavier I. Rivera | Lora Inclán | José M. Guillén-Rodríguez